Data from the Recently Published GENIA Study Show that Genous Is Associated with Low Rates of Stent Thrombosis and Target Lesion Revascularization

HONG KONG,  OrbusNeich today reported clinical data showing that the Genous Stent is safe and effective for the treatment of patients with ST-segment elevation myocardial infarction (STEMI). Published in Revista Española de Cardiología, the data from the GENIA study show low rates of stent thrombosis (ST) and target lesion revascularization (TLR) at a mean follow-up of 538 ± 334.72 days.

In the prospective observational study, which included 139 consecutive patients undergoing primary angioplasty with implantation of one or more Genous Stents, the TLR rate was 3.8 percent and the rate of definite ST was 1.4 percent. In addition, the rate of the rate of cardiac death was 2.9 percent (four patients), and the target vessel revascularization (TVR) was 5.8 percent.

“STEMI is a highly prothrombotic clinical situation for which the choice of the most appropriate stent remains controversial,” said Melisa Santas-Alvarez, M.D., of the Departamento de Cardiología Intervencionista, Hospital Clínico de Santiago de Compostela, Spain, and first author of the study. “In high-risk situations like STEMI, drug eluting stents can delay healing of the vessel and have been associated with increased risk of thrombosis. We believe that the Genous Stent’s ability to accelerate endothelialization may reduce the risk of ST. These results add to the growing body of knowledge confirming the safety and efficacy of Genous in STEMI patients.”

In the GENIA study, the average patient age was 64 ± 13.5 years, and 74.8 percent of patients were male. Notably, 20.1 percent of patients had multivessel disease. Patients were prescribed a regimen of antithrombotic and anticoagulant therapy in accordance with the European guidelines for the management of acute myocardial infarction.

Source: OrbusNeich